Related Experiment Video
Updated: Jan 6, 2026
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Design, Synthesis, And Evaluation Of Cyanopyridines As Anti-Colorectal Cancer Agents Via Inhibiting STAT3 Pathway
Lingyuan Xu1,2,3, Lingxi Shi1,2,3, Sensen Qiu4
1Department of Colorectal Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, People's Republic of China.
Background:
Colorectal cancer is one of the common malignant tumors. Cyanopyridine and aminocyanopyridine having a carbon-nitrogen bond have been shown to have significant anticancer effects. STAT3 is a promising therapeutic target in multiple cancers. However, there are currently no effective STAT3 inhibitors in clinical practice for the treatment of colorectal cancer.
Materials And Methods:
We screened 27 cyanopyridines for their anticancer activity by cell viability. The HCT-116, RKO, and DLD-1 cell lines were used to evaluate the anti-colorectal cancer effect of 3n. Scratch experiments and colony formation assays were used for the assessment of cell migration and proliferation capacity. Phosphorylated STAT3, STAT3, MCL-1, and Survivin levels were assessed by Western blot analysis.
Results:
In this study, we synthesized 27 cyanopyridines and screened their anticancer activities in three human tumor cells, HCT-116, Hela229, and A375. We found that 2-amino-3-cyanopyridine 3n has better anticancer activity with IC50 values in the low micromolar range. Furthermore, 3n significantly inhibited the migration and colony formation of colorectal cancer cells. Mechanistically, 3n inhibited the expression of STAT3 phosphorylation in a dose- and time-dependent manner.
Conclusion:
3n is worth of further investigations toward the discovery of STAT3 inhibitor as a drug candidate for cancer therapy.
Insights
A novel cyanopyridine derivative, 3n, shows significant anticancer activity against colorectal cancer by inhibiting STAT3 phosphorylation. This compound warrants further investigation as a potential STAT3 inhibitor drug candidate for cancer therapy.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Colorectal cancer is a prevalent malignancy.
- Cyanopyridines exhibit anticancer properties.
- STAT3 is a key target in cancer, but effective inhibitors are lacking for colorectal cancer.
Purpose of the Study:
- To synthesize and screen cyanopyridine derivatives for anticancer activity.
- To evaluate the efficacy of compound 3n against colorectal cancer cells.
- To investigate the mechanism of action of 3n, focusing on STAT3 signaling.
Main Methods:
- Synthesis and screening of 27 cyanopyridine compounds.
- Assessment of cell viability, migration (scratch assay), and proliferation (colony formation assay) in colorectal cancer cell lines (HCT-116, RKO, DLD-1).
- Western blot analysis to determine levels of phosphorylated STAT3, STAT3, MCL-1, and Survivin.
Main Results:
- Compound 2-amino-3-cyanopyridine (3n) demonstrated potent anticancer activity with IC50 values in the low micromolar range.
- 3n significantly inhibited colorectal cancer cell migration and colony formation.
- 3n dose- and time-dependently inhibited STAT3 phosphorylation.
Conclusions:
- Compound 3n shows promising anticancer effects against colorectal cancer.
- 3n's mechanism involves the inhibition of STAT3 phosphorylation.
- Further research into 3n as a STAT3 inhibitor drug candidate for cancer therapy is warranted.
